Hikma Pharmaceuticals (HKMPF)
(Delayed Data from OTC)
$25.70 USD
0.00 (0.00%)
Updated Sep 13, 2024 02:56 PM ET
2-Buy of 5 2
A Value A Growth C Momentum A VGM
Income Statements
Fiscal Year end for Hikma Pharmaceuticals Plc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2,875 | 2,517 | 2,553 | 2,341 | 2,207 |
Cost Of Goods | 1,485 | 1,279 | 1,252 | 1,140 | 1,059 |
Gross Profit | 1,390 | 1,238 | 1,301 | 1,201 | 1,148 |
Selling & Adminstrative & Depr. & Amort Expenses | 1,023 | 956 | 719 | 622 | 655 |
Income After Depreciation & Amortization | 367 | 282 | 582 | 579 | 493 |
Non-Operating Income | 9 | 32 | 31 | 48 | 65 |
Interest Expense | 95 | 81 | 69 | 69 | 67 |
Pretax Income | 281 | 233 | 544 | 558 | 491 |
Income Taxes | 89 | 42 | 124 | 128 | 4 |
Minority Interest | 2 | 3 | -1 | -1 | 1 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 192 | 191 | 420 | 430 | 487 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 190 | 188 | 421 | 431 | 486 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 608 | 641 | 715 | 658 | 583 |
Depreciation & Amortization (Cash Flow) | 241 | 359 | 133 | 79 | 90 |
Income After Depreciation & Amortization | 367 | 282 | 582 | 579 | 493 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 222.37 | 225.00 | 233.00 | 238.00 | 243.00 |
Diluted EPS Before Non-Recurring Items | 2.21 | 1.80 | 1.93 | 1.71 | 1.50 |
Diluted Net EPS (GAAP) | 0.85 | 0.84 | 1.81 | 1.81 | 2.00 |
Fiscal Year end for Hikma Pharmaceuticals Plc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | NA | NA | NA | NA |
Cost Of Goods | NA | NA | NA | NA | NA |
Gross Profit | NA | NA | NA | NA | NA |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Non-Operating Income | NA | NA | NA | NA | NA |
Interest Expense | NA | NA | NA | NA | NA |
Pretax Income | NA | NA | NA | NA | NA |
Income Taxes | NA | NA | NA | NA | NA |
Minority Interest | NA | NA | NA | NA | NA |
Investment Gains/Losses | NA | NA | NA | NA | NA |
Other Income/Charges | NA | NA | NA | NA | NA |
Income From Cont. Operations | NA | NA | NA | NA | NA |
Extras & Discontinued Operations | NA | NA | NA | NA | NA |
Net Income (GAAP) | NA | NA | NA | NA | NA |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | NA | NA | NA | NA | NA |